Mid-size CRO consolidation: Chiltern completes Theorem deal

By Dan Stanton contact

- Last updated on GMT

Mid-size consolidation: Chiltern completes Theorem merger
Mid-size consolidation: Chiltern completes Theorem merger
Chiltern has completed its acquisition of Theorem, making it the self-declared “largest mid-sized” CRO.

A month after the announcement was made, mid-sized contract research organisation (CRO) Chiltern has finalised its acquisition of fellow mid-size player, creating a clinical trial services firm comprising of 3,700 people across 47 countries.

“We have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service,”​ Chiltern CEO Jim Esinhart said. “Clients can expect the same high level of service, now with expanded capabilities.”

Chiltern Chairman Nick Thornton added: “We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas.”

Through the deal, the company expands its Oncology, Biopharma and Source offerings, and established new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.

While the CRO industry is dominated by the top eight players​ – Quintiles, Covance, PRA, Parexel, PPD, Icon, INC and inVentiv – Chiltern can offer comprehensive, yet flexible and responsive, clinical development services, the company says, while Senior leadership can continue to be involved in running trials.

Fellow mid-sized player SynteractHCR recently shared a similar opinion to Outsourcing-Pharma.com​, suggesting customers like working with a mid-sized CRO as it retains personal attention but across a global network.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers